Cookies on the
LGC website
We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we’ll assume that you are happy to receive all cookies on the LGC website. However, if you would like to, you can change your cookie settings at anytime.
Question markFind out more

Dr. Juergen Mueller joins LGC as Commercial and Strategic Development Director, Oligo-therapeutics

22 Sep 2017

LGC is delighted to announce that Dr Juergen Mueller has joined as Commercial and Strategic Development Director, Oligo-therapeutics.

Juergen brings with him a wealth of knowledge and an extensive global network of contacts in the field of oligo-therapeutics development and manufacture.  He has a PhD in synthetic chemistry and maintains links with the University of Basel occasionally teaching chemistry students.

David Griffiths, Managing Director, Pharma & Health Solutons, LGC, said, “I’m delighted to welcome Juergen to our expanding Oligonucleotide team.  Juergen will define and deliver growth in our oligo-therapeutic business across the Group. He will develop our existing customer base at Axolabs, Biosearch and our bioanalytical and CMC analytical drug development services (DDS) teams – especially those for whom we are providing discovery and preclinical support as they scale up and progress candidate drugs to the clinic – all of which will help us as we work towards our vision of science for a safer world.”